InnoCare Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

InnoCare Pharma şirketinin toplam hissedar öz sermayesi CN¥6.9B ve toplam borcu CN¥1.6B olup, bu da borç-öz sermaye oranını 23.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥9.7B ve CN¥2.7B dir.

Anahtar bilgiler

23.2%

Borç/özkaynak oranı

CN¥1.61b

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥7.30b
Eşitlik	CN¥6.94b
Toplam yükümlülükler	CN¥2.74b
Toplam varlıklar	CN¥9.68b

Son finansal sağlık güncellemeleri

Recent updates

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Oct 21

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Sep 13

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Jun 21

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

Apr 02

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Feb 14

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Oct 06

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

May 11

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Apr 11

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Jan 25

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Sep 05

InnoCare Pharma (HKG:9969) Is Using Debt Safely

Apr 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 9969 'nin kısa vadeli varlıkları ( CN¥8.1B ) kısa vadeli yükümlülüklerini ( CN¥2.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 9969 şirketinin kısa vadeli varlıkları ( CN¥8.1B ) uzun vadeli yükümlülüklerini ( CN¥637.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 9969 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 9969 şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 9969 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 9969 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

InnoCare Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Recent updates

Is InnoCare Pharma (HKG:9969) A Risky Investment?

InnoCare Pharma Limited Announces Phase II Clinical Study of Icp-488 for the Treatment of Moderate-To-Severe Plaque Psoriasis

InnoCare Pharma Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients

InnoCare Pharma Limited to Report Q3, 2024 Results on Nov 12, 2024

InnoCare Pharma Limited Announces Board and Committee Changes

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

InnoCare Pharma Limited Announces End of Phase 2 Meeting with the U.S. Food and Drug Administration Regarding the Clinical Development of Orelabrutinib for the Treatment of Multiple Sclerosis

Consensus estimates of losses per share improve by 12%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

InnoCare Pharma Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S

InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China

InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023)

Consensus revenue estimates decrease by 16%

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

New minor risk - Profitability

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Third quarter 2023 earnings released: CN¥0.062 loss per share (vs CN¥0.28 loss in 3Q 2022)

New minor risk - Profitability

InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Second quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.24 loss in 2Q 2022)

Innocare Pharma Limited Announces Board Changes

InnoCare Pharma Limited to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates upgraded to CN¥0.38 loss

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.08 loss in 1Q 2022)

No longer forecast to breakeven

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2022

InnoCare Pharma Limited Announces the Latest Clinical Result of FGFR Inhibitor Gunagratinib (ICP-192) for the Treatment of Cholangiocarcinoma Was Presented At 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium

Is InnoCare Pharma (HKG:9969) A Risky Investment?

InnoCare Pharma Limited Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

Now 27% undervalued

No longer forecast to breakeven

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China

InnoCare Pharma Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore

Consensus revenue estimates increase by 12%

Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.17 profit in 3Q 2021)

Less than half of directors are independent

InnoCare Pharma Limited to Report Nine Months, 2022 Results on Nov 11, 2022

InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China

Forecast to breakeven in 2024

InnoCare Pharma Limited has completed a Follow-on Equity Offering in the amount of CNY 2.672498 billion.

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA